Table 1.
Clinical characteristics of the patients
| Patient classification | All patients (N = 50) |
EGFR-TKI naïve patients (N = 32) | EGFR-TKI acquired-resistance patients (N = 18) |
|---|---|---|---|
| Age, year, median (IQR) | 67.5 (59.8–73.3) | 68.5 (58.3–73.8) | 67.5 (62.7–73.5) |
| Sex, female | 25 (50.0%) | 14 (43.8%) | 11 (61.1%) |
| Smoking status | |||
| Non-smoker | 25 (50.0%) | 13 (40.6%) | 12 (66.7%) |
| Ex-smoker | 14 (28.0%) | 9 (28.1%) | 5 (27.8%) |
| Current smoker | 11 (22.0%) | 10 (31.3%) | 1 (5.6%) |
| Tumor EGFR mutation | |||
| Exon 19 deletion | 22 (44.0%) | 10 (31.3%) | 12 (66.7%) |
| L858R | 15 (30.0%) | 9 (28.1%) | 6 (33.3%) |
| Wild-type | 13 (26.0%) | 13 (40.6%) | 0 |
| Histology | |||
| Adenocarcinoma | 50 | 32 | 18 |
EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor; IQR interquartile range